Q1 2014 13F Holders as of 3/31/2014
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
11M
-
Shares change
-
+11M
-
Total reported value, excl. options
-
$201M
-
Value change
-
+$200M
-
Number of buys
-
34
-
Price
-
$18.18
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q1 2014
35 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q1 2014.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11M shares
of 108M outstanding shares and own 10.24% of the company stock.
Largest 10 shareholders include FMR LLC (4.38M shares), BlackRock Advisors LLC (1.06M shares), Redmile Group, LLC (1M shares), FRANKLIN RESOURCES INC (840K shares), Visium Asset Management, LP (700K shares), ADAGE CAPITAL PARTNERS GP LLC (400K shares), WALL STREET ASSOCIATES (394K shares), BlackRock Group LTD (341K shares), VANGUARD GROUP INC (338K shares), and Broadfin Capital, LLC (224K shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.